aggregating predictive wisdom formulating critical estimations exploring calibrated understanding crowdsourcing definitive futures delivering contingent wisdom mapping the future mapping accurate contingencies composing probable forecasts predicting critical insights modeling predictive forecasts delivering contingent predictions calculating precise forecasts generating quantitative estimations delivering calibrated estimations

Question

Metaculus Help: Spread the word

If you like Metaculus, tell your friends! Share this question via Facebook, Twitter, or Reddit.

When will Trikafta become available for Cystic Fibrosis patients on the NHS (England)?

Cystic Fibrosis is a genetic disease affecting mainly the lungs and the pancreas.(1) In 2012 an American company called Vertex Pharmaceuticals got approval from the FDA to market a drug called Ivacaftor, the first generation of "CFTR Modulators" which improves lung function in people with CF.(2) It was initially priced at $300,000 a year making it one of the most expensive drugs on the market.

This was followed by Orkambi ($270,000 a year) in 2015,(3) and then in October 2019 by Trikafta, a triple combination therapy which is effective in around 90% of people with CF. Trikafta is marketed at around $300,000. However, the initial evidence is that it is much more effective at improving lung function in CF patients than previous therapies.(4)

Because of the cost of Orkambi, NICE, the organisation responsible for evaluating drugs affordability and effectiveness decided that the drug did not meet its quality of life standards and recommended not fund it.(5) NHS England and Vertex then negotiated to get a deal to reduce the price, but it took until October 2019 for NHS England to reach a deal to make Orkambi available to all eligible CF patients.(6) This question asks:

When will Trikafta become available for Cystic Fibrosis patients on the NHS (England)?

By 'available for Cystic Fibrosis patients', we mean that there are at least 5535 English CF patients who must have access to Trikafta via the NHS.

{{qctrl.predictionString()}}

Metaculus help: Predicting

Predictions are the heart of Metaculus. Predicting is how you contribute to the wisdom of the crowd, and how you earn points and build up your personal Metaculus track record.

The basics of predicting are very simple: move the slider to best match the likelihood of the outcome, and click predict. You can predict as often as you want, and you're encouraged to change your mind when new information becomes available.

The displayed score is split into current points and total points. Current points show how much your prediction is worth now, whereas total points show the combined worth of all of your predictions over the lifetime of the question. The scoring details are available on the FAQ.

Note: this question resolved before its original close time. All of your predictions came after the resolution, so you did not gain (or lose) any points for it.

Note: this question resolved before its original close time. You earned points up until the question resolution, but not afterwards.

This question is not yet open for predictions.

Thanks for predicting!

Your prediction has been recorded anonymously.

Want to track your predictions, earn points, and hone your forecasting skills? Create an account today!

Track your predictions
Continue exploring the site

Community Stats

Metaculus help: Community Stats

Use the community stats to get a better sense of the community consensus (or lack thereof) for this question. Sometimes people have wildly different ideas about the likely outcomes, and sometimes people are in close agreement. There are even times when the community seems very certain of uncertainty, like when everyone agrees that event is only 50% likely to happen.

When you make a prediction, check the community stats to see where you land. If your prediction is an outlier, might there be something you're overlooking that others have seen? Or do you have special insight that others are lacking? Either way, it might be a good idea to join the discussion in the comments.